Update on the acute treatment of hereditary angioedema.
暂无分享,去创建一个
[1] J. Biedenkapp,et al. Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency , 2013 .
[2] M. Mannesse,et al. Immunogenicity Assessment of Recombinant Human C1-Inhibitor , 2012, BioDrugs.
[3] J. Stockman. Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2012 .
[4] J. Nuijens,et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.
[5] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.
[6] W. Lumry,et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] A. Kaplan,et al. The bradykinin-forming cascade and its role in hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[8] W. Pullman,et al. Hypersensitivity Reactions Following Ecallantide Treatment for Acute Attacks of HAE , 2010 .
[9] J. Bernstein,et al. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability , 2010, Expert review of clinical immunology.
[10] J. Bernstein,et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.
[11] B. Zuraw,et al. Pathogenesis and laboratory diagnosis of hereditary angioedema. , 2009, Allergy and asthma proceedings.
[12] K. Wyrwich,et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema , 2009, Quality of Life Research.
[13] T. Craig,et al. When is prophylaxis for hereditary angioedema necessary? , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[14] K. Andersen,et al. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. , 2009, European journal of dermatology : EJD.
[15] M. Cicardi,et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. , 2009, Trends in molecular medicine.
[16] B. Zuraw. Clinical practice. Hereditary angioedema. , 2008, The New England journal of medicine.
[17] A. Davis,et al. New treatments addressing the pathophysiology of hereditary angioedema , 2008, Clinical and molecular allergy : CMA.
[18] K. Bork,et al. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[19] B. Zuraw. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[20] M. Cicardi,et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema , 2007, Expert opinion on pharmacotherapy.
[21] T. Craig,et al. Fresh frozen plasma for the treatment of hereditary angioedema. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[22] K. Khair,et al. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option , 2006, Clinical and experimental immunology.
[23] M. Frank. Hereditary angioedema: the clinical syndrome and its management in the United States. , 2006, Immunology and allergy clinics of North America.
[24] M. Levi,et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. , 2006, The Journal of allergy and clinical immunology.
[25] K. Bork,et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema , 2005, Transfusion.
[26] A. Eerenberg,et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.
[27] H. Longhurst. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? , 2005, International journal of clinical practice.
[28] L. Romics,et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.
[29] A. Tordai,et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.
[30] J. Lindner,et al. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a review , 2003 .
[31] A. Adinoff. Treatment of 193 Episodes of Laryngeal Edema with C1 Inhibitor Concentrate in Patients with Hereditary Angioedema , 2002, Pediatrics.
[32] A. Davis,et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. , 2002, The Journal of clinical investigation.
[33] M. Cicardi,et al. Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.
[34] M. Cicardi,et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. , 1980, Annals of allergy.
[35] J. Gelfand,et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. , 1980, The New England journal of medicine.